FDA approves Vertex's first-in-class non-opioid analgesic for acute pain
Vertex Stock Jumps After Non-Opioid Painkiller Gets FDA Approval
Shares of Vertex Pharmaceuticals rose 8% in off-hours trading after the pharmaceutical company won U.S. approval for the [first new non-opioid painkiller in decades](
Vertex Pharmaceuticals stock is soaring. The FDA just approved its potentially game-changing pain treatment.
GE HealthCare Technologies Inc. (GEHC): FDA-Cleared AI Ultrasound Systems for Women’s Health
We recently published a list of 10 AI News and Ratings Too Important to Miss. In this article, we are going to take a look at where GE HealthCare Technologies Inc. (NASDAQ:GEHC) stands against other AI news and ratings too important to miss.
Jim Cramer Says ‘I Want You To Sell Viking Therapeutics, Inc. (VKTX) And Roll It Into Viking Holdings’
We recently published an article titled Jim Cramer’s Lightning Rounds: 9 Stocks in Focus. In this article, we are going to take a look at where Viking Therapeutics, Inc. (NASDAQ:VKTX) stands against the other stocks.
Axsome gets FDA approval for Symbravo for migraine
Axsome Therapeutics (NASDAQ:AXSM) has received FDA approval for its drug Symbravo for the acute treatment of migraine with or without aura in adults. Symbravo, a combination of meloxicam and rizatriptan,
Nasdaq4d
Alvotech: FDA To Review BLA For AVT05 - Quick Facts
The FDA review process is anticipated to be completed ... and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Founded in the late 1990s by Andrew Mariathasan in New ...
OKYO Pharma insiders buy shares amid clinical trials
LONDON - OKYO Pharma Limited (NASDAQ: OKYO), a biopharmaceutical company engaged in developing treatments for ocular conditions, has reported insider share purchases on the NASDAQ. The company's CEO,
Eagle-Tribune18h
Vertex Announces FDA Approval of JOURNAVX™ (suzetrigine), a First-in-Class Treatment for Adults With Moderate-to-Severe Acute Pain
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) has approved JOURNAVX™ (suzetrigine), an oral, non-opioid, highly selective NaV1.8 pain signal inhibitor for the treatment of adults with moderate-to-severe acute pain.
Atara to cut 50% of workforce amid FDA woes
Atara Biotherapeutics (NASDAQ:ATRA) has announced plans to cut around 50% of its workforce, just a little over a week after it said the FDA had declined to approve its immunotherapy Ebvallo. The biotech company said it expects to recognize approximately $7.
Flex Ltd. (NASDAQ:FLEX) Q3 2025 Earnings Call Transcript
Q3 2025 Earnings Call Transcript January 29, 2025 Flex Ltd. beats earnings expectations. Reported EPS is $0.77, expectations were $0.64. Operator: Thank you for standing by. Welcome to Flex’s Third Quarter Fiscal 2025 Earnings Conference Call.
Journey Medical: FDA Approval For Emrosi Makes This An Exciting Stock
The approval Journey Medical received from FDA for Emrosi makes DERM an exciting stock. Click here to read more.
Biotech Stocks Facing FDA Decision In February 2025
February is observed as American Heart Month, a period dedicated to raising awareness about heart health. The first American Heart
Vertex Pharmaceuticals Shares Gain After FDA Approves Non-Opioid Pain Drug
Shares of Vertex Pharmaceuticals rose after Journavx, the company's oral non-opioid pain medication, received Food and Drug Administration approval. The Boston company's stock rose 4.3%, to $457.25, after hours Thursday. Journavx, or suzetrigine, was approved for treatment of adults with moderate-to-severe acute pain.